Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st—Modifier Gene Therapy For The Treatment Of Stargardt Disease
May 27 (Reuters) - Ocugen Inc OCGN.O:
OCUGEN ANNOUNCES RARE PEDIATRIC DISEASE DESIGNATION GRANTED FOR OCU410ST—MODIFIER GENE THERAPY FOR THE TREATMENT OF STARGARDT DISEASE
OCUGEN INC: PLANS TO INITIATE PHASE 2/3 PIVOTAL CONFIRMATORY TRIAL IN FEW WEEKS WITH TARGET BLA IN 2027
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

What company Is ASML? Between ASML and AMD, Which Is a Better Investment?

Amazon Stock: 4 Pillars Supporting a Buy Thesis in a Cautious Market

Tradingkey








